000275609 001__ 275609
000275609 005__ 20240229154943.0
000275609 0247_ $$2doi$$a10.1002/cam4.5896
000275609 0247_ $$2pmid$$apmid:37096432
000275609 0247_ $$2altmetric$$aaltmetric:146534517
000275609 037__ $$aDKFZ-2023-00815
000275609 041__ $$aEnglish
000275609 082__ $$a610
000275609 1001_ $$00000-0002-5892-8886$$aMahamat-Saleh, Y.$$b0
000275609 245__ $$aMetabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition.
000275609 260__ $$aHoboken, NJ$$bWiley$$c2023
000275609 3367_ $$2DRIVER$$aarticle
000275609 3367_ $$2DataCite$$aOutput Types/Journal article
000275609 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687349954_6283
000275609 3367_ $$2BibTeX$$aARTICLE
000275609 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275609 3367_ $$00$$2EndNote$$aJournal Article
000275609 500__ $$a2023 Jun;12(11):12668-12682
000275609 520__ $$aExcess body fatness and hyperinsulinemia are both associated with an increased risk of postmenopausal breast cancer. However, whether women with high body fatness but normal insulin levels or those with normal body fatness and high levels of insulin are at elevated risk of breast cancer is not known. We investigated the associations of metabolically defined body size and shape phenotypes with the risk of postmenopausal breast cancer in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition.Concentrations of C-peptide-a marker for insulin secretion-were measured at inclusion prior to cancer diagnosis in serum from 610 incident postmenopausal breast cancer cases and 1130 matched controls. C-peptide concentrations among the control participants were used to define metabolically healthy (MH; in first tertile) and metabolically unhealthy (MU; >1st tertile) status. We created four metabolic health/body size phenotype categories by combining the metabolic health definitions with normal weight (NW; BMI < 25 kg/m2 , or WC < 80 cm, or WHR < 0.8) and overweight or obese (OW/OB; BMI ≥ 25 kg/m2 , or WC ≥ 80 cm, or WHR ≥ 0.8) status for each of the three anthropometric measures separately: (1) MHNW, (2) MHOW/OB, (3) MUNW, and (4) MUOW/OB. Conditional logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs).Women classified as MUOW/OB were at higher risk of postmenopausal breast cancer compared to MHNW women considering BMI (OR = 1.58, 95% CI = 1.14-2.19) and WC (OR = 1.51, 95% CI = 1.09-2.08) cut points and there was also a suggestive increased risk for the WHR (OR = 1.29, 95% CI = 0.94-1.77) definition. Conversely, women with the MHOW/OB and MUNW were not at statistically significant elevated risk of postmenopausal breast cancer risk compared to MHNW women.These findings suggest that being overweight or obese and metabolically unhealthy raises risk of postmenopausal breast cancer while overweight or obese women with normal insulin levels are not at higher risk. Additional research should consider the combined utility of anthropometric measures with metabolic parameters in predicting breast cancer risk.
000275609 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000275609 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275609 650_7 $$2Other$$abody mass index
000275609 650_7 $$2Other$$abreast cancer
000275609 650_7 $$2Other$$aconcentrations of C-peptide
000275609 650_7 $$2Other$$ametabolic health
000275609 650_7 $$2Other$$awaist circumference
000275609 650_7 $$2Other$$awaist-to-hip ratio
000275609 7001_ $$00000-0002-6846-1204$$aRinaldi, S.$$b1
000275609 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, R.$$b2$$udkfz
000275609 7001_ $$aBiessy, C.$$b3
000275609 7001_ $$aGonzalez-Gil, E. M.$$b4
000275609 7001_ $$aMurphy, N.$$b5
000275609 7001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b6$$udkfz
000275609 7001_ $$00000-0002-9637-3869$$aHuerta, J. M.$$b7
000275609 7001_ $$aSieri, S.$$b8
000275609 7001_ $$aTjønneland, A.$$b9
000275609 7001_ $$00000-0001-9222-6215$$aMellemkjaer, L.$$b10
000275609 7001_ $$aGuevara, M.$$b11
000275609 7001_ $$aOvervad, K.$$b12
000275609 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, A.$$b13
000275609 7001_ $$00000-0002-7303-061X$$aTin Tin, S.$$b14
000275609 7001_ $$aPadroni, L.$$b15
000275609 7001_ $$aSimeon, V.$$b16
000275609 7001_ $$aMasala, G.$$b17
000275609 7001_ $$aMay, A.$$b18
000275609 7001_ $$aMonninkhof, E.$$b19
000275609 7001_ $$00000-0001-9219-4436$$aChristakoudi, S.$$b20
000275609 7001_ $$00000-0001-6517-1300$$aHeath, A. K.$$b21
000275609 7001_ $$00000-0002-8452-8472$$aTsilidis, K.$$b22
000275609 7001_ $$aAgudo, A.$$b23
000275609 7001_ $$aSchulze, M. B.$$b24
000275609 7001_ $$aRothwell, J.$$b25
000275609 7001_ $$aCadeau, C.$$b26
000275609 7001_ $$00000-0001-7157-419X$$aSeveri, S.$$b27
000275609 7001_ $$00000-0003-2237-0128$$aWeiderpass, E.$$b28
000275609 7001_ $$aGunter, M. J.$$b29
000275609 7001_ $$aDossus, L.$$b30
000275609 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.5896$$gp. cam4.5896$$n11$$p12668-12682$$tCancer medicine$$v12$$x2045-7634$$y2023
000275609 909CO $$ooai:inrepo02.dkfz.de:275609$$pVDB
000275609 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275609 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000275609 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000275609 9141_ $$y2023
000275609 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:13Z
000275609 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:13Z
000275609 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-04-16T15:13:13Z
000275609 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-30
000275609 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000275609 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000275609 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000275609 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000275609 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2021-04-16T15:13:13Z
000275609 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000275609 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000275609 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275609 980__ $$ajournal
000275609 980__ $$aVDB
000275609 980__ $$aI:(DE-He78)C020-20160331
000275609 980__ $$aUNRESTRICTED